Healthcare Industry News: EnLight
News Release - April 12, 2012
EDAP Installs Ablatherm-HIFU at Dedicated HIFU Clinic in PolandLYON, France, April 12, 2012 -- (Healthcare Sales & Marketing Network) -- EDAP TMS SA (Nasdaq:EDAP ), a global leader in therapeutic ultrasound, announced the installation of its Ablatherm-HIFU device at the HIFU Clinic in Warsaw, Poland. The HIFU Clinic provides prostate cancer patients in Poland with access to Ablathem-HIFU treatment performed by a dedicated team of leading urologists and oncologists. Since installation, nine Ablatherm-HIFU treatments have been performed in Poland.
The dedicated clinic was established in late 2011 by the AMEDS Centrum, a team of medical experts and specialists in the fields of urology, cardiology, neurology, sexology, and interventional radiology. An advisory board, comprised of the key opinion leaders in urology in Poland, was formed in March 2012 to raise visibility for Ablatherm-HIFU as a clinically validated, minimally invasive treatment option for prostate cancer patients.
Marek Filipek, MD, Leader of HIFU Clinic Medical Team, commented, "Prostate cancer kills ten men in Poland daily. HIFU is a revolutionary technique, treating cancer non-invasively with lower side effects as compared to traditional treatment options. I am seeing a growing interest regarding HIFU amongst my colleagues. I'm very excited that we can now offer thermal ablation for Polish patients. I'm also very pleased to have the possibility of cooperating with some of the most experienced HIFU specialists, such as Dr. Stefan Thuroff from Munich."
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "The launch of a HIFU Clinic with AMEDS Centrum in Warsaw grows our footprint in Europe and continues the Ablatherm-HIFU expansion in major international markets. This dedicated urology practice will draw upon the expertise of key opinion leaders in Poland to communicate the clinical efficacy of our robotized device to prostate cancers across this major European country."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm(R), the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA, the EnLight U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith(R) range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
In addition to historical information, this press release may contain forward-looking statements that involve risks and uncertainties. Such statements are based on management's current expectations and are subject to a number of uncertainties, including the uncertainties of the regulatory process, and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.
Source: EDAP TMS
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.